Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA.
about
Antibiotic-free selection in biotherapeutics: now and foreverPreferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infectionMultiple genes repress motility in uropathogenic Escherichia coli constitutively expressing type 1 fimbriae.Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle.Use of zebrafish to probe the divergent virulence potentials and toxin requirements of extraintestinal pathogenic Escherichia coli.A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectorsAttenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathwayAntibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium.Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human Vaccine productionPlasmid addiction systems: perspectives and applications in biotechnology.An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plagueThe global regulator Ler is necessary for enteropathogenic Escherichia coli colonization of Caenorhabditis elegansDevelopment of bioluminescent bioreporters for in vitro and in vivo tracking of Yersinia pestis.Mechanisms involved in Escherichia coli and Serratia marcescens removal during activated sludge wastewater treatment.Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain.Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection.Bacterial infectious disease control by vaccine development.Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains.Helicobacter pylori arginase mutant colonizes arginase II knockout mice.A quorum sensing-based in vivo expression system and its application in multivalent bacterial vaccineOral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.Yersinia pestis Requires Host Rab1b for Survival in Macrophages.Enteric pathogens as vaccine vectors for foreign antigen deliveryAttenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growthEnhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.Involvement of mismatch repair in the reciprocal control of motility and adherence of uropathogenic Escherichia coli.Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tractNew technologies in developing recombinant attenuated Salmonella vaccine vectors.Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment.Inhibition of tumor growth using salmonella expressing Fas ligand.Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.Salmonella enterica serovar Typhi live vector vaccines finally come of ageRecombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic Escherichia coli for kidney infection.Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines.Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.New technologies in using recombinant attenuated Salmonella vaccine vectors.
P2860
Q27028105-C9E7544A-6B5E-423B-A504-D1D214E180CDQ27321660-2C4ED363-A9C3-49E8-87DB-6E9F627AE6E3Q30482051-DE60B371-3536-4CEB-84FE-2E5F84776AE3Q33455526-BED68425-423E-47B9-BE41-17E9E083D7DCQ33519502-173EACFF-D82B-483E-A613-968D5E003A81Q33557714-35C0C013-294A-4DAE-9DB2-ECA7C7F9AD2BQ33597022-B1FA4925-81EA-4783-8D6A-F359ACA65FD6Q33768314-C3880F0F-6365-4169-99BD-FD74B8325324Q33769332-53F5B924-C701-4E0F-9979-1F69BD27900CQ34006127-F1C18058-CB39-41D3-A3C9-0B632B85E617Q34120959-AD698AB7-5E3F-414C-9EFF-A731BECFFA77Q34160193-4E239503-B354-4FB6-823F-D94D34631B5CQ34163944-FE0BEFCA-F9BD-4C78-AB70-0E7CE015E67DQ34300974-FBB90076-72FA-46EA-B136-0B86D3D88F66Q34447928-E205B31B-3933-4ACC-A476-D0DB2A4138EDQ34523881-99FDE8FF-282A-4003-9689-7EA0D422436AQ34529634-F6D8A49A-33AF-4BD6-8BA2-C6726FC79AA3Q34716080-1B52D3C8-85E0-42CC-B0B9-7755191C4FD3Q34739590-F44EDE3B-148D-4605-A1A4-40600D70B91BQ34785982-8706A0E3-8F59-4024-99D1-2651AAD5FBA3Q34851811-1C58D661-5817-4BB8-85E0-B6C0B832BCE9Q35177981-3AA33F0A-2A93-4E34-BE37-512B59A70840Q35213546-97922EE1-1EB7-410D-88E1-32B4F7E870BEQ35783791-C859AFE9-6011-4C3C-996F-C334FDE97BF5Q35818586-6C9A41DE-FFF8-4574-AD49-FA4942752E6DQ35896020-089D2961-1F16-47C7-8BC9-ABDF1862D28BQ35921725-EAD43DEA-0F7F-4BA8-94E8-DD080F0D5BFCQ35949699-A2C4BFA0-4C0F-41C2-807E-92779733E251Q36018122-F7A19DC0-3AAF-46CD-BA6E-A2ACD1A0FF53Q36082306-5A810799-58E2-466E-BC69-EF1A8236CF76Q36653379-75FF1545-1E29-440D-97C6-D198ADD0A4FCQ36756869-CD1AD5AF-078E-4E1C-BFEA-36AB40CC1B88Q36812613-2EF0DB24-DA20-4527-998C-7C71CD22C0FEQ36898558-DD949B1B-5F54-496F-B6B1-25912D7F95C8Q37106127-9D75F800-B2D2-4F35-B55C-2806E0D84B40Q37235277-7740E6A9-A14E-442E-B854-35EE68A60F38Q37329929-BC2E78AA-A66A-4386-AEA2-8F87C1822652Q37582872-E42AF95A-0193-4DD3-84DE-FC39DE902CC8Q37623663-C8D6BF52-D235-4630-BC83-84CD82F30F7FQ37674803-E7B1F4C7-C508-411D-8B59-59E153031776
P2860
Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@en
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@nl
type
label
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@en
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@nl
prefLabel
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@en
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@nl
P2093
P2860
P1476
Optimization of plasmid mainte ...... Salmonella typhi CVD 908-htrA.
@en
P2093
M B Sztein
M K Tanner
M M Levine
S S Wasserman
P2860
P304
P407
P577
1999-12-01T00:00:00Z